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TO THE EDITOR
Non-melanoma skin cancer is the most
prevalent cancer in man. For reasons
that are unclear non-melanoma skin
cancer is dramatically increased in
organ transplant recipients (OTRs)
compared with immunocompetent pa-
tients (non-OTRs) (Euvrard et al., 2003).
Increased risk of metastasis and the
presence of multiple tumors are a
significant source of morbidity in OTRs.
These patients present with different
types of non-melanoma skin cancer
with squamous cell carcinoma (SCC)
and keratoacanthoma (KA) particularly
prevalent. The genetic aberrations
driving these cancers in OTRs and
non-OTRs are poorly understood.
Receptor tyrosine kinases are fre-
quently activated by somatic mutations
and/or amplification in human cancers,
particularly in epithelial tumors. To
determine whether receptor tyrosine
kinases are mutated in SCC, we
searched the literature to identify re-
ceptor tyrosine kinases that have a role
in epidermal homeostasis and thus
could be candidate oncogenes in squa-
mous lesions. We chose to analyze
epidermal growth factor receptor
(EGFR) that is highly expressed in a
small subset of metastatic cutaneous
SCCs (Bauknecht et al., 1985; Shimizu
et al., 2001; Maubec et al., 2005);
fibroblast growth factor receptor 3
(FGFR3) that is mutated in familial
acanthosis nigricans and Crouzon’s
syndrome, a type of craniosynostosis
(Berk et al., 2007) and induces acantho-
sis and benign tumors in transgenic
mice (Logie et al., 2005); and fibroblast
growth factor receptor 2 (FGFR2),
which is also mutated in Crouzon’s
syndrome and in this disease is asso-
ciated with acanthosis nigricans
(Meyers et al., 1995). We included the
insulin-like growth factor receptor 1
(IGF1R) mice lacking this receptor have
hypoplastic skin (Liu et al., 1993; De
Moerlooze et al., 2000) and MET, the
receptor for the ligand hepatocyte
growth factor. Mice overexpressing the
MET receptor exhibit an enhanced
number of hair follicles and accelerated
hair follicle morphogenesis (Lindner
et al., 2000), a feature associated with
cyclosporine use in OTRs. Finally, we
assessed ERBB2, which induces SCCs
when targeted to mouse skin (Kiguchi
et al., 2000).
We determined the mutation status
of the kinase domains of EGFR, IGF1R,
MET and ERBB2, and the regions of
FGFR2 and FGFR3 that are mutated in
Crouzon’s syndrome in a cohort of 95
tumors that consisted of 70 SCCs and
25 KAs from 55 OTR and 40 non-OTR
tumors; not every tumor was analyzed
for every gene. Genomic DNA was
extracted from archival formalin-fixed
paraffin-embedded samples and ampli-
fied with M13 sequence-tailed primers
(Supplementary Table 1).
Mutations were found in EGFR,
FGFR2, and FGFR3 but not in ERRB2,
MET, and IGF receptor 1 (Table 1). The
somatic nature of the mutations was
confirmed by sequencing the adjacent
normal skin in all three cases in which
mutations were found. EGFR was
mutated in 1 of 40 (2.5%) SCCs, a
frequency not dissimilar to that de-
tected in head and neck SCCs (7.3%)
(Willmore-Payne et al., 2006). The
particular Y727H mutation we found
in exon 18 of EGFR has been observed
in SCC of the lung (Pallis et al., 2007).
In addition to mutational activation,
amplification of wild-type EGFR can
drive tumorigenesis in a variety of
cancers and in head and neck SCC cell
lines (Weichselbaum et al., 1989). In a
dataset of array-based comparative
Abbreviations: FGFR, fibroblast growth factor receptor; KA, keratoacanthoma; OTR, organ transplant
recipient; RTK, receptor tyrosine kinase; SCC, squamous cell carcinoma
www.jidonline.org 901
K Ridd and BC Bastian
Somatic Mutation of EGFR in SCC
genomic hybridization of a larger co-
hort of SCCs (n¼ 268, 173 OTR tumors
and 95 non-OTR tumors) and KAs
(n¼46, 27 OTR tumors and 19 non-
OTR tumors), we found amplifications
of the EGFR region on chromosome 7
in three SCCs (1.1%) but not in
KAs (Figure 1a) (K. Ridd et al., manu-
script in preparation). Interestingly, all
of the tumors harboring an EGFR
amplification were from non-OTRs.
The amplifications were confirmed by
fluorescence in situ hybridization (Fig-
ure 1b). The tumor with the EGFR
mutation had no amplification of EGFR,
and the three tumors with amplification
did not show any mutations. We also
analyzed EGFR protein levels in 275
SCCs (157 OTR tumors and 118 non-
OTR tumors) and 69 KAs (28 OTR
tumors and 41 non-OTR tumors) using
tissue microarrays. EGFR was overex-
pressed compared with adjacent nor-
mal skin in 19 of the 275 SCCs (6.9%)
tumors and none of the KAs (Figure 1c
and d). EGFR was significantly over-
expressed in a greater number of non-
OTR SCCs (14/118 (11.8%)) compared
with OTR SCCs (5/157 (3.1%))
(Po0.0001). Amplification of EGFR
was associated with high EGFR protein
levels by immunohistochemistry and a
representative image is shown in Figure
1c. There was not sufficient tissue to
determine the EGFR protein level in the
single tumor with an EGFR mutation.
EGFR overexpression was not asso-
ciated with an increased phosphory-
lated extracellular signal-regulated
kinase expression (data not shown),
but phosphorylated extracellular sig-
nal-regulated kinase levels generally
do not correlate with EGFR activation
even in cancers with a demonstrated
pathogenetic role for EGFR such as
non-small cell lung cancer (Vicent
et al., 2004; Han et al., 2005; Conde
et al., 2006; Sonobe et al., 2007;
Hosokawa et al., 2009). This is ex-
plained by the extensive feedback
mechanisms that exist for MAPK signal-
ing (Citri and Yarden 2006; Amit et al.,
2007).
We found a somatic mutation of
FGFR2 in 1 of 41 SCCs (2.4%) and
in none of 19 KAs. The P303L
mutation found in exon 8 is different
from the somatic mutations found in
primary uterine tumors or endometrial
cell lines (Pollock et al., 2007) and
the germline mutations found in cra-
niosynostosis syndromes (Kan et al.,
2002).
Mutations in FGFR3 were detected
in 1 of 17 (6%) KA, but were not found
in a series of 41 SCCs. Interestingly, the
mutation was found in exon 7 (A265T)
and thus differs from the mutations of
FGFR3 described in seborrheic kera-
toses, bladder, and cervical cancer
(Cappellen et al., 1999; Logie et al.,
2005). Our results are concordant with
a previous study that did not report
mutations in FGFR3 in SCC (Karoui
et al., 2001).
No mutations were found in IGF1R,
and to date mutations have not been
reported in human cancers. Mutations
Table 1. List of mutations detected
SCC KA
OTRs Non-OTRs OTR Non-OTR Mutated codon
EGFR 1/18 0/22 0/10 0/9 Y727H
ERBB2 0/10 0/12 0/9 0/7 NA
FGFR2 0/19 1/22 0/10 0/9 P303L
FGFR3 0/20 0/21 1/8 0/9 A265E
IGF1R 0/10 0/9 0/10 0/5 NA
MET 0/19 0/21 0/11 0/9 NA
FGFR, fibroblast growth factor receptor; IGFR, IGF receptor; KA, keratoacanthoma; NA, not
applicable; ND, not determined; OTR, organ transplant recipient; SCC, squamous cell carcinoma.
Specific regions of each kinase were analyzed and included the kinase domains of EGFR, ERBB2,
IGF1R and MET, and the regions of FGFR2 and FGFR3 that are mutated in neoplastic conditions and
Crouzon’s syndrome.
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Figure 1. Amplification of EGFR in squamous cell carcinomas (SCCs). (a) Array comparative genomic
hybridization profile showing amplification of EGFR (arrow) on chromosome 7 in an SCC.
(b) Fluorescence in situ hybridization showing two copies of the control centromeric probe
for chromosome 7 (green) and increased copy number of a probe for EGFR (red). Bar¼10 mm.
(c and d) Representative case of an SCC with amplification of EGFR and concomitant overexpression
of EGFR protein by immunohistochemistry. Lesional (c) and non-lesional skin (d). Bar¼ 0.1 mm.
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were also absent in MET in our sam-
ples, but mutations have been found in
renal cell carcinomas and in 25% of
SCC of the head and neck (Schmidt
et al., 1999; Di Renzo et al., 2000).
Finally, we did not find mutations in
ERBB2 in non-melanoma skin cancer,
consistent with studies on SCC of the
head and neck (Willmore-Payne et al.,
2006).
Our study identifies genetic activa-
tion of EGFR by mutation or amplifica-
tion in a small subset of SCC. EGFR is a
validated therapeutic target in other
cancers, and approved drugs targeting
EGFR exist, so that this finding may
provide a therapeutic opportunity for a
small subset of patients with advanced
SCC refractory to conventional treat-
ment. Future studies will have to con-
firm whether EGFR activation is indeed
more frequent in non-OTRs as sug-
gested by the mutation pattern in our
dataset. By contrast, somatic mutations
in other receptor tyrosine kinases found
in other epithelial cancers and hyper-
proliferative epidermal conditions are
not a common finding in cutaneous
SCC.
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